| Name | Title | Contact Details |
|---|---|---|
Victoria Larco |
Associate Director, Professional Marketing | Profile |
Laura Carter |
Head of Total Rewards | Profile |
Jeffrey Nau |
President and Chief Executive Officer | Profile |
David Benadon |
Chief Human Resources Officer | Profile |
Seamlessly integrating patient-specific surgical planning and navigation, professional education and rehearsal experiences with incredible VR-empowered patient engagement capabilities
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
Rondo-Pak is a global print and packaging specialist providing effective solutions and comprehensive services to the pharmaceutical and life sciences industries. The company`s portfolio of sophisticated packaging solutions addresses precise requirements for compliance, child resistance, anti-counterfeiting e-pedigree and more. Rondo-Pak has been a recognized leader in pharmaceutical folding cartons for over 70 years, and is a proud part of the Körber Medipak network of companies.
Medical Center Compounding is a Cleveland, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that leverages its strength in small molecule drug technologies to bring important new medicines to patients.